NDC 16571-821 – Temozolomide
Temozolomide 250 mg/1 · Capsule · Oral
Product NDC16571-821
Product details
- Brand name
- Temozolomide
- Generic name
- Temozolomide
- Labeler
- Rising Pharma Holdings, Inc.
- Dosage form
- Capsule
- Route
- Oral
- Marketing category
- ANDA · ANDA206309
- Marketed since
- October 4, 2022
- Listing expires
- December 31, 2026
- Pharmacologic class
- Alkylating Drug
Active ingredients
- Temozolomide 250 mg/1
Package NDC codes (2)
| Package NDC | Description | Since |
|---|---|---|
| 16571-821-02 | 20 CAPSULE in 1 BOTTLE (16571-821-02) | Oct 4, 2022 |
| 16571-821-51 | 5 CAPSULE in 1 BOTTLE (16571-821-51) | Oct 4, 2022 |
Recalls mentioning this NDC
- D-0384-2026 Mar 11, 2026 · Class II
Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing
Other Temozolomide products
- 16729-048 Temozolomide 5 mg/1 · Capsule · Accord Healthcare Inc.
- 16729-049 Temozolomide 20 mg/1 · Capsule · Accord Healthcare Inc.
- 16729-050 Temozolomide 100 mg/1 · Capsule · Accord Healthcare Inc.
- 16729-051 Temozolomide 250 mg/1 · Capsule · Accord Healthcare Inc.
- 16729-129 Temozolomide 140 mg/1 · Capsule · Accord Healthcare Inc.
- 16729-130 Temozolomide 180 mg/1 · Capsule · Accord Healthcare Inc.
- 65162-802 Temozolomide 20 mg/1 · Capsule · Amneal Pharmaceuticals LLC
- 65162-801 Temozolomide 5 mg/1 · Capsule · Amneal Pharmaceuticals LLC
- 65162-805 Temozolomide 180 mg/1 · Capsule · Amneal Pharmaceuticals LLC
- 65162-804 Temozolomide 140 mg/1 · Capsule · Amneal Pharmaceuticals LLC
- 65162-803 Temozolomide 100 mg/1 · Capsule · Amneal Pharmaceuticals LLC
- 65162-806 Temozolomide 250 mg/1 · Capsule · Amneal Pharmaceuticals LLC